Citicoline: A Candidate for Adjunct Treatment of Multiple Sclerosis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Remitting-relapsing multiple sclerosis (RR-MS) involves autoimmune attacks on myelin, followed by repair attempts.
• Current disease-modifying therapies (DMTs) primarily target myelin damage and often exhibit toxicity.
• Enhancing myelin repair is a critical unmet need in MS management.

Purpose of the Study:

• To investigate the potential of citicoline as a therapeutic agent for promoting myelin repair in multiple sclerosis (MS).
• To evaluate citicoline's efficacy in preclinical models relevant to MS pathology.

Main Methods:

• Citicoline was tested in experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced demyelination rodent models.
• Visual evoked potentials (VEPs) in glaucoma patients, an indicator of neural pathway function, were assessed following citicoline treatment.

Main Results:

• Citicoline demonstrated significant efficacy in both EAE and cuprizone-induced rodent models of MS.
• Citicoline treatment improved VEPs in glaucoma patients, suggesting potential benefits for neural pathway function relevant to MS.

Conclusions:

• Citicoline exhibits potential as a myelin repair-enhancing agent for multiple sclerosis (MS).
• Its efficacy in preclinical models and positive effects on VEPs suggest further clinical evaluation for MS remyelination is warranted.